Filana Therapeutics Inc (FLNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.82-0.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FLNA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | — | 41.1 | 41.1 | 41.1 | 10.9 | 11.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | 41.1 | 41.1 | 41.1 | 10.9 | 11.5 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 15.7 | 26.6 | 69.6 | 89.4 | 68.0 | 24.8 | — | — | 3.0 | 7.6 | 9.2 | 9.1 | 7.3 | 4.9 | 7.6 | 8.3 |
| Operating Income | (46.0) | (95.4) | (141.4) | (106.0) | (80.0) | (32.9) | (6.4) | (5.0) | (6.7) | (11.9) | (15.0) | (14.2) | (12.4) | 31.4 | (3.9) | (3.5) |
| Earnings from Continuing Operations | ||||||||||||||||
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | — | — | — | (14.1) | (12.4) | 31.5 | — | (2.6) |
| Income Tax Expense | 0.0 | — | 0.0 | — | — | — | — | — | — | — | — | (0.1) | (0.1) | (0.1) | — | (1.5) |
| Net Income | ||||||||||||||||
| Net Income | (42.3) | (91.0) | (24.3) | (97.2) | (76.2) | (32.4) | (6.3) | (4.6) | (6.6) | (11.9) | (14.9) | (14.1) | (12.4) | 31.5 | (3.4) | (2.6) |
| Per Share | ||||||||||||||||
| Basic EPS | — | (1.88) | (0.53) | (2.32) | (1.90) | (0.82) | — | — | — | — | — | (0.31) | (0.27) | 0.70 | — | — |
| Diluted EPS | — | (1.88) | (1.46) | (2.32) | (1.90) | — | — | — | — | — | — | (0.31) | (0.27) | 0.70 | — | — |
| Basic Weighted Avg Shares | — | 48.3 | 46.3 | 41.9 | 40.2 | 39.4 | — | — | — | — | — | 45.8 | 45.3 | 45.0 | — | — |
| Diluted Weighted Avg Shares | — | 48.3 | 46.6 | 41.9 | 40.2 | — | — | — | — | — | — | 45.8 | 45.3 | 45.2 | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | (6.4) | (4.9) | (6.6) | (11.9) | (14.9) | (14.2) | (12.4) | 31.5 | (3.8) | (3.4) |
| EBIT | (46.0) | (95.4) | (141.4) | (106.0) | (80.0) | (32.9) | (6.4) | (5.0) | (6.7) | (11.9) | (15.0) | (14.2) | (12.4) | 31.4 | (3.9) | (3.5) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | — | 0.5% | 0.6% | -0.2% | — | 57.8% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.